Skip to main content

OvaGene Inks Deal for miRNA Biomarkers for Cancer Drug Response

Premium

OvaGene said this week that it has signed a licensing and collaboration agreement with the Moffitt Cancer Center to develop microRNAs as biomarkers for cancer drug response.

OvaGene said it now has the exclusive rights to to develop and commercialize assays based on miRNAs validated by Moffitt researcher Johnathan Lancaster. The company said it would initially focus on a test that can predict an ovarian cancer patient's response to treatment, and expects to have a product ready for market in 18 to 24 months.

The firm said it would create additional assays to predict drug response to other gynecologic cancers in the future.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.